PodParley PodParley
PodParley
Sacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial Cancer episode artwork

EPISODE · Jun 22, 2022 · 8 MIN

Sacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial Cancer

from Oncology Learning Network · host HMP Global

Petros Grivas, MD, from the University of Washington Fred Hutchinson Cancer Research Center, shares results from the TROPHY-U-01 phase 2 trial evaluating the use of sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Episode metadata supplied by the publisher feed · Published Jun 22, 2022

Embed this episode

Ready to play

Sacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial Cancer

0:00 8:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 8 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on June 22, 2022.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!